Phase II miss dims outlook for Biogen’s anti-tau mAb from Bristol deal

Biogen is terminating development of gosuranemab to treat primary tauopathies following a mid-stage clinical failure, but the move won’t scuttle a Phase II trial of the anti-tau mAb to treat Alzheimer’s disease.

Biogen Inc. (NASDAQ:BIIB) said Friday that gosuranemab (BIIB092) failed to significantly improve disability associated with progressive supranuclear palsy as measured by the PSP rating scale at week 52, missing the primary endpoint in the Phase II PASSPORT trial. The mAb also missed secondary endpoints in the study...